10-K: Cardio Diagnostics Holdings, Inc. Details Capital Structure and Regulatory Landscape in 10-K Filing

Cardio Diagnostics Holdings, Inc. outlines its capital stock, warrants, and regulatory environment in its annual 10-K filing, highlighting its focus on cardiovascular disease diagnostics.

Summary

• Cardio Diagnostics Holdings, Inc. has two classes of securities registered under the Securities Exchange Act of 1934: common stock and public warrants, trading under the symbols CDIO and CDIOW on the Nasdaq Capital Market.
• The company is authorized to issue 300,000,000 shares of common stock and 100,000,000 shares of preferred stock, both with a par value of $0.00001 per share.
• Each share of common stock is entitled to one vote, and holders do not have cumulative voting rights.
• Holders of common stock are entitled to dividends as declared by the Board of Directors, subject to the preferential rights of preferred stock holders and contractual limitations.
• In the event of liquidation, holders of common stock will participate pro rata in remaining assets after payment of liabilities, subject to the rights of preferred stock holders.
• Public warrants allow holders to purchase one share of common stock at $11.50 per share, expiring on October 25, 2027, and are subject to adjustment.
• The company is obligated to maintain a current prospectus for the shares underlying the warrants, and may redeem the warrants for $0.01 each under certain conditions, including a stock price of $18.00 or more for 20 trading days within a 30-day period.
• The company is subject to Section 203 of the DGCL, which regulates corporate takeovers, and its certificate of incorporation requires that certain lawsuits be brought in the Court of Chancery of the State of Delaware.
• The company's bylaws provide that special meetings of stockholders may be called only by a majority vote of the board, the CEO, or the chairman, and also specify advance notice requirements for stockholder proposals and director nominations.
• The company earned $950 in revenue in 2022 and $17,065 in 2023, and is focusing on establishing relationships with larger organizations to increase adoption of its solutions.
• The company has secured an Innovative Technology Contract from Vizient, Inc., and Family Medicine Specialists is implementing its heart attack risk assessment test, Epi+Gen CHD.
• The company believes its Epi+Gen CHD and PrecisionCHD tests are categorized as laboratory-developed tests (LDTs) and do not require FDA premarket authorization under current enforcement discretion policy.
• The company is evaluating an FDA regulatory pathway to enable broader access to its tests.
• The company estimates a US addressable market of $51 billion for Epi+Gen CHD, $134 billion for PrecisionCHD, and $53 billion each for congestive heart failure and stroke tests, and $49 billion for diabetes tests.
• The company is setting up an internal operational hub that includes a CLIA laboratory, with completion anticipated in 2024 or 2025.
• The company has a patent portfolio including five patent families, with issued patents in multiple countries and pending applications worldwide.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has innovative technology and strategic partnerships, its financial performance is weak, with low revenue and significant losses. The company also faces regulatory and competitive risks, and has a history of raising capital through dilutive means. The company's future success is highly dependent on its ability to scale operations, secure payor coverage, and manage its cash burn.

Positives

• The company has a diversified product pipeline targeting major cardiovascular diseases and associated co-morbidities.
• The company has secured key partnerships with Vizient, Inc. and Family Medicine Specialists, indicating market interest.
• The company has obtained CPT PLA codes for both Epi+Gen CHD and PrecisionCHD tests, which is a key step for payor coverage.
• The company has a strong intellectual property portfolio with multiple patents and pending applications.
• The company is developing a cardiovascular risk intelligence platform, HeartRisk, to augment its clinical blood tests.

Negatives

• The company has generated only nominal revenue to date, with $17,065 in 2023 and $950 in 2022.
• The company has incurred significant net losses, totaling $8,376,834 in 2023 and $4,660,985 in 2022.
• The company relies on a limited number of suppliers and a single contract laboratory, which poses supply chain risks.
• The company is subject to complex and evolving regulations, including FDA and CLIA requirements.
• The company may face intense competition from companies with greater resources and longer operating histories.

Risks

• The company has a limited operating history and may not achieve or maintain profitability.
• The market for epigenetic tests is new and unproven, and may not grow as expected.
• The company may be unable to obtain and maintain regulatory clearance or approval for its tests.
• The company may be unable to compete effectively with other companies in the cardiovascular diagnostics market.
• The company may be unable to raise needed financing in the future on acceptable terms.
• The company may be unable to maintain its listing on The Nasdaq Stock Market.
• The company's business could be negatively impacted by the potential short and long-term impact of a re-emergence of COVID-19 variants or any other pandemic.
• The company relies on a limited number of suppliers, contract manufacturers, and logistics providers, and its tests are currently performed by a single contract high complexity CLIA laboratory.
• The company's license agreement with University of Iowa Research Foundation (UIRF) includes a non-exclusive license of technical information that potentially could grant unaffiliated third parties access to materials and information considered derivative work made by us, which could be used by such licensees to develop competitive products.
• The company may be subject to general litigation that may materially adversely affect us and our operations.

Future Outlook

The company plans to expand its product pipeline, pursue payor coverage, target multiple revenue channels, and evaluate an FDA regulatory pathway. The company also intends to launch a new lab and fulfillment center to expand testing capacity and improve margins.

Management Comments

• The company aspires to give every American adult insight into their unique risk for various cardiovascular diseases.
• The company aims to become one of the leading medical technology companies for enabling improved prevention, detection, treatment and management of cardiovascular disease and associated co-morbidities.
• The company believes that incorporating its solutions into routine clinical practice in and prevention efforts can help alter the trajectory that nearly one in two Americans is expected to develop some form of cardiovascular disease by 2035.

Industry Context

The company operates in the cardiovascular diagnostic testing market, which is estimated to grow from $8.47 billion in 2022 to $12.41 billion by 2027, with a CAGR of 7.94%. The market is driven by an aging population, the rise of chronic diseases, the shift to value-based care, the growth of telemedicine, the adoption of AI, and the rise of patient engagement.

Comparison to Industry Standards

• The company's Epi+Gen CHD test demonstrated a 76% and 78% sensitivity for men and women, respectively, for three-year CHD risk, compared to 44% and 32% for the Framingham Risk Score and ASCVD Pooled Cohort Equation.
• The company's PrecisionCHD test demonstrated an overall average area under the curve, sensitivity, and specificity of 82%, 79%, and 76%, respectively, for detecting coronary heart disease, compared to 58% sensitivity for exercise ECG.
• The company's tests are based on epigenetic biomarkers, which are dynamic and can change over time, unlike static genetic biomarkers, potentially allowing for personalized interventions and monitoring of effectiveness.
• The company's tests are designed to be more accessible and convenient than traditional methods, such as stress echocardiograms, which require in-person visits and can take weeks to schedule.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential loss of investment due to the company's financial performance.
• Employees may be affected by the company's ability to secure funding and maintain operations.
• Customers may benefit from the company's innovative diagnostic solutions, but may also face uncertainty regarding the company's long-term viability.
• Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.

Next Steps

• The company plans to launch a new lab and fulfillment center to expand testing capacity and improve margins.
• The company intends to expand its product pipeline to include tests for stroke, congestive heart failure, and diabetes.
• The company will continue to build clinical and health economics evidence to pursue payor coverage.
• The company will focus on expanding adoption of its products across key channels, including health systems and self-insured employers.
• The company will continue to evaluate an FDA regulatory pathway to enable broader access to its tests.

Key Dates

Keywords

cardiovascular disease, epigenetics, diagnostics, coronary heart disease, clinical tests, warrants, FDA, CLIA, biomarkers, AI, machine learning, HeartRisk, PrecisionCHD, Epi+Gen CHD